Cullinan Oncology Llc Stock Performance
| CGEM Stock | USD 19.02 0.14 0.74% |
On a scale of 0 to 100, Cullinan Oncology holds a performance score of 7. The firm shows a Beta (market volatility) of 1.26, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cullinan Oncology will likely underperform. Please check Cullinan Oncology's total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether Cullinan Oncology's price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cullinan Oncology LLC are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent technical and fundamental indicators, Cullinan Oncology displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.74 | Five Day Return (12.39) | Year To Date Return 79.6 | Ten Year Return (36.41) | All Time Return (36.41) |
Last Split Factor 2:1 | Last Split Date 2009-08-31 |
1 | Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICAB Antibody, CLN-619, as Monotherapy and in Combination with a Checkp... | 04/24/2024 |
2 | Disposition of 20277 shares by Jennifer Michaelson of Cullinan Oncology at 28.54 subject to Rule 16b-3 | 05/03/2024 |
3 | Disposition of 5606 shares by Jennifer Michaelson of Cullinan Oncology at 30.06 subject to Rule 16b-3 | 05/07/2024 |
4 | Cullinan Therapeutics executive sells over 1.7m in stock | 05/08/2024 |
5 | Cullinan Oncology, Inc. Insider Sells 1628060.00 in Stock - Defense World | 05/10/2024 |
6 | Insider Trading | 05/15/2024 |
7 | CGEM Stock Earnings Cullinan Oncology Beats EPS for Q1 2024 | 05/16/2024 |
8 | Disposition of 16475 shares by Ebeling Thomas of Cullinan Oncology at 12.73 subject to Rule 16b-3 | 05/23/2024 |
9 | Affinity Asset Advisors LLC Acquires New Position in Cullinan Therapeutics, Inc. - MarketBeat | 06/05/2024 |
10 | Disposition of 18450 shares by Ebeling Thomas of Cullinan Oncology at 13.0 subject to Rule 16b-3 | 06/07/2024 |
11 | Disposition of tradable shares by Nguyen Nate of Cullinan Oncology subject to Rule 16b-3 | 06/11/2024 |
12 | Cullinan Therapeutics, Inc. Shares Acquired by Parkman Healthcare Partners LLC - MarketBeat | 06/14/2024 |
| Begin Period Cash Flow | 156.2 M |
Cullinan |
Cullinan Oncology Relative Risk vs. Return Landscape
If you would invest 1,553 in Cullinan Oncology LLC on March 20, 2024 and sell it today you would earn a total of 349.00 from holding Cullinan Oncology LLC or generate 22.47% return on investment over 90 days. Cullinan Oncology LLC is currently generating 0.5807% in daily expected returns and assumes 6.4297% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Cullinan, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cullinan Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cullinan Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cullinan Oncology LLC, and traders can use it to determine the average amount a Cullinan Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0903
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CGEM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.43 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.58 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Cullinan Oncology is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cullinan Oncology by adding it to a well-diversified portfolio.
Cullinan Oncology Fundamentals Growth
Cullinan Stock prices reflect investors' perceptions of the future prospects and financial health of Cullinan Oncology, and Cullinan Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cullinan Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 666.36 M | ||||
| Shares Outstanding | 57.63 M | ||||
| Price To Earning | 5.23 X | ||||
| Price To Book | 3.27 X | ||||
| Price To Sales | 26.88 X | ||||
| Gross Profit | 18.94 M | ||||
| EBITDA | (190.34 M) | ||||
| Net Income | (153.16 M) | ||||
| Cash And Equivalents | 611 M | ||||
| Cash Per Share | 13.40 X | ||||
| Total Debt | 3.59 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.04 X | ||||
| Book Value Per Share | 9.88 X | ||||
| Cash Flow From Operations | (134.28 M) | ||||
| Earnings Per Share | (3.13) X | ||||
| Market Capitalization | 1.1 B | ||||
| Total Asset | 485.1 M | ||||
| Retained Earnings | (200.86 M) | ||||
| Working Capital | 452.05 M | ||||
About Cullinan Oncology Performance
To evaluate Cullinan Oncology LLC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Cullinan Oncology generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Cullinan Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Cullinan Oncology LLC market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Cullinan's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -5.7 K | -6 K | |
| Return On Tangible Assets | (0.32) | (0.30) | |
| Return On Capital Employed | (0.42) | (0.40) | |
| Return On Assets | (0.32) | (0.30) | |
| Return On Equity | (0.34) | (0.32) |
Things to note about Cullinan Oncology LLC performance evaluation
Checking the ongoing alerts about Cullinan Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cullinan Oncology LLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cullinan Oncology is way too risky over 90 days horizon | |
| Cullinan Oncology appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (153.16 M) with profit before overhead, payroll, taxes, and interest of 18.94 M. | |
| Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4. | |
| Cullinan Oncology has a poor financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Cullinan Therapeutics, Inc. Shares Acquired by Parkman Healthcare Partners LLC - MarketBeat |
- Analyzing Cullinan Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cullinan Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Cullinan Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cullinan Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cullinan Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cullinan Oncology's stock. These opinions can provide insight into Cullinan Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Information and Resources on Investing in Cullinan Stock
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.13) | Return On Assets (0.22) | Return On Equity (0.29) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.